Thugmuffin
4年前
$NSTM NovelStem Announces FDA Pre-Submission and EMA In Vitro Diagnostic Device Filing for Revolutionary Life-Saving, Treatment-Changing Diagnostic Device by 30%-Owned NewStem, LtdPress Release | 04/11/2022
Jerusalem, Israel and Boca Raton, Florida--(Newsfile Corp. - April 11, 2022) - NovelStem International Corp. (OTC Pink: NSTM), a biotechnology company focused on the stem cell-based technology platform developed by 30%-owned, Israel-based NewStem Ltd., today announced NewStem's filing of a pre-submission to the FDA for a De Novo Request and an in vitro diagnostic device (IVDD) for Europe, the Middle East and Africa (EMA) for their NewStem Software Diagnostic Device. The announcement followed the company's graduation from Illumina's Accelerator 3rd funding cycle in March 2022.
The NewStem Software Diagnostic Device (NSDD) is a bioinformatics-based software medical device platform that provides oncologists with information regarding the presence of mutations in tumors, which may confer patient resistance to certain anti-cancer drugs. The information provided by NSDD will aid oncologists when deciding which treatment regime to apply.
Cancer is the second leading cause of death globally. Despite efforts and achievements made in treating cancer over the past several decades, resistance to anti-cancer drugs continues to be a major problem in cancer therapies. Resistance is the leading cause of relapses in cancer and one of the significant causes of death due to the disease. Drug resistance (whether pre-existing or generated after therapy) is responsible for over 90% of deaths in cancer patients receiving traditional chemotherapeutics or novel targeted drugs treatments.
NewStem is a biotechnology company established as a bio-platform for genome wide screenings based on proprietary Haploid human Embryonic Stem Cell (HhESC) technology. These cells can potentially change how we develop genetic based therapeutics and diagnostics, as they are superior to other cells used for whole genome screenings. NewStem is currently the only company worldwide to develop innovative practice-changing products based on this innovative and exclusive technology. NewStem is now raising funds to deepen its internal personnel capabilities and for further research and development of its pipeline products.
"The technology, based on our proprietary haploid cells, has changed the dogma and enables what was formerly impossible," says NewStem founder and Chief Scientific Officer, Prof. Nissim Benvenisty. "NSDD will give oncologists a better understanding of the many variances that present challenges in the treatment of cancer and in the identification of drug-type resistance. That is unprecedented."
About NewStem newstem.com
NewStem Ltd., a biotechnology spinoff of Yissum, The Hebrew University of Jerusalem's technology-transfer company, has established a bio-platform for genome wide screenings based on proprietary Haploid human Embryonic Stem Cell (HhESC) technology. These cells can potentially change the way we develop genetic based therapeutics and diagnostics, as they are superior to other cells used for whole genome screenings. NewStem is currently the only company worldwide to develop innovative practice-changing products based on this innovative and exclusive technology. NewStem utilizes this bio-platform for the discovery and development of precision oncology drugs based on synthetic lethal interaction modality and for diagnostics of anti-cancer drugs resistance. NewStem's licensed technology is based on the research of Professor Nissim Benvenisty, Director of the Azrieli Center for Stem Cells and Genetic Research at the Hebrew University. NewStem holds the intellectual property, reagents and experience required for HhESC isolation, differentiation, genetic manipulation, immunogenicity and tumorigenicity.
About NovelStem International Corp. www.novelstem.com
NovelStem owns a 30% stake in NewStem Ltd. which is advancing its novel stem-cell-based diagnostic technology for predicting patients' resistance to cancer therapies, allowing for better, targeted cancer treatments with the potential to reduce incidents of drug resistance. The technology is also being used for genetic research related to other medical therapies.
Forward-Looking Statements
Statements in this press release and its hyperlinks may be "forward-looking statements" within the meaning of federal securities laws. The matters discussed herein that are forward-looking statements are based on current board and management expectations that involve risks and uncertainties that may result in such expectations not being realized. Actual outcomes and results may differ materially from what is expressed or forecasted in such forward-looking statements due to numerous potential risks and uncertainties, including, but not limited to, the success of NewStem's research and future commercialization of its diagnostics utilizing human haploid pluripotent stem cells, competition in the area of genetic diagnostics, the ability to retain key personnel involved in research and development, the ability to secure appropriate regulatory approvals, and the ability to fund future investment in NewStem. Such forward-looking statements speak only as of the date on which they are made.
# # #
NovelStem Investor Relations
Bill Jones and David Collins
Catalyst IR
(212) 924-9800
NSTM@catalyst-ir.com
NewStem Contact
Ayelet Dilion-Mashiah - CEO
NewStem Ltd.
+972-54-5725477
ayelet@newstem.com
AskMuncher
5年前
$NSTM NovelStem Announces NewStem, Ltd. Was Selected by Illumina for its Global Illumina Accelerator
Press Release | 09/20/2021
Boca Raton, Florida and Jerusalem, Israel--(Newsfile Corp. - September 20, 2021) - NovelStem International Corp. (OTC Pink: NSTM), a biotechnology company focused on the stem cell-based technology platform developed by 30%-owned Israel-based, NewStem, Ltd., announced that NewStem, along with six other genomic companies, was selected by Illumina for its global Illumina Accelerator. Illumina Accelerator is a company creation engine that focuses on partnering with and building companies with unique genomic technologies. Illumina Accelerator provides selected companies with access to seed investment, access to Illumina sequencing systems and reagents, as well as business guidance, genomics expertise, and fully operational lab space. Under the Illumina Accelerator - NewStem agreement, NewStem is entitled to a match funding for new capital of up to $5.5 million within 18 months.
NewStem has developed a novel stem-cell-based technology platform for the development of therapeutics and diagnostics. Using this technology, NewStem has identified and completed the analysis of resistance to the most frequently prescribed standard-of-care cancer treatments. NewStem is a spinoff of Yissum, The Hebrew University of Jerusalem's technology-transfer company. NewStem holds intellectual property rights related to stem cells, including genome-wide screening methodologies and its main patents were granted in United States, Europe, Japan and Israel and are in national phase in additional countries.
NewStem's diagnostic technology is based on the research of specialized stem cells that carry just one set of chromosomes (haploid cells) by Professor Nissim Benvenisty, Director of the Azrieli Center for Stem Cells and Genetic Research at the Hebrew University. NewStem's most advanced solution is a diagnostic and database that enables NewStem to predict patients' resistance to certain anti-cancer therapies, allowing for better, targeted personal-oncology treatments with the potential to reduce incidents of anti-cancer drug resistance, which occur in nearly 50% of all cancer cases.
NewStem CEO, Ayelet Dilion-Mashiah, commented, "We are very excited to be selected by Illumina, the global leader in DNA sequencing and array-based technologies, for this program. In addition to potential capital and professional support, we believe selection to the Illumina Accelerator further validates the significant potential of NewStem's therapeutic and diagnostic development technology and will assist us in bringing our first products to market and potentially advancing additional commercial solutions."
Amanda Cashin, PhD, co-Founder and Global Head of Illumina For Startups said, "The global reach of Illumina Accelerator is demonstrated by our investment in these seven diverse startups from six countries. This diversity is testament to the strength and breadth of the talented entrepreneurs around the world focused on unlocking the power of the genome to improve human health and beyond."
About NovelStem International Corp. www.novelstem.com
NovelStem owns an approximate 30% stake in NewStem Ltd. which is advancing its novel stem-cell-based diagnostic technology for predicting patients' resistance to cancer therapies, allowing for better, targeted cancer treatments with the potential to reduce incidents of drug resistance. The technology is also being used for genetic research related to other medical therapies. Based on a share purchase agreement from 2018, NovelStem has invested $4M in NewStem and also owns a 50% stake in Netco Partners.
About NewStem Ltd.
NewStem Ltd. is advancing novel stem-cell-based technology utilized for the development of new therapeutics and diagnostics. The most advanced product of NewStem is a diagnostic predicting patients' resistance to cancer therapy, allowing for better, targeted personal-oncology treatments with the potential to reduce incidents of anti-cancer drug resistance. NewStem is a spinoff of Yissum, The Hebrew University of Jerusalem's technology-transfer company. NewStem's solutions are based on the research of human haploid pluripotent stem cells (hHPSCs) by Professor Nissim Benvenisty, Director of the Azrieli Center for Stem Cells and Genetic Research at the Hebrew University. NewStem holds the intellectual property, reagents and experience required for hHPSC isolation, differentiation, genetic manipulation, immunogenicity and tumorigenicity.
Forward-Looking Statements
Statements in this press release and its hyperlinks may be "forward-looking statements" within the meaning of federal securities laws. The matters discussed herein that are forward-looking statements are based on current board and management expectations that involve risks and uncertainties that may result in such expectations not being realized. Actual outcomes and results may differ materially from what is expressed or forecasted in such forward-looking statements due to numerous potential risks and uncertainties, including, but not limited to, the success of NewStem's research and future commercialization of its diagnostics utilizing human haploid pluripotent stem cells, competition in the area of genetic diagnostics, the ability to retain key personnel involved in research and development, the ability to secure appropriate regulatory approvals, and the ability to fund future investment in NewStem. Such forward-looking statements speak only as of the date on which they are made.
# # #
NovelStem Investor Relations
Bill Jones or David Collins
Catalyst IR
(212) 924-9800
NSTM@catalyst-ir.com
funnyG986
6年前
NSTM 0.08 X 0.1 missed this news in December; NovelStem Increases NewStem Ownership to 27.3% Following Achievement of Development Milestones for Stem-Cell-Based Cancer Treatments Resistance Diagnostic
https://apnews.com/44feba749aace8d6654c39ba7db5097a
BOCA RATON, Fla. and JERUSALEM, Israel, Dec. 16, 2019 (GLOBE NEWSWIRE) -- NovelStem International Corp. (OTC Pink: NSTM ), a biotechnology company focused on stem-cell-based diagnostic technology to aid the selection of cancer therapeutic agents being developed by its Israel-based affiliate, NewStem Ltd., today announced it has completed a $1 million follow-on investment in NewStem, increasing its ownership in NewStem to 27.3% from 20%.
The additional investment was made following NewStem’s successful, on-time completion of the first milestone requirements established at the time of its initial investment in July 2018. This included set up and analysis of resistance to five anti-cancer treatments that are the standard-of-care, enabling it to further develop diagnostics for identifying patient resistance to those treatments. In July 2018, NovelStem also secured the right to increase its ownership in NewStem up to 33% pursuant to second milestone requirements. NovelStem expects to further increase its ownership following NewStem’s achievement of these second milestone requirements, relating to the identification of patient resistance to three additional standard-of-care anti-cancer treatments, increasing the total to eight drugs. Upon achievement of the second milestone, NovelStem will increase its ownership to 33% through the investment of an additional $1 million.
Drug resistance in tumors is a major cause of cancer treatment failure, yet in nearly 50% of cancer cases this resistance is recognized only after the completion of the first course of treatment. NewStem’s diagnostic technology can predict patients’ resistance to anti-cancer drugs prior to treatment, potentially allowing for better, targeted cancer treatments and related cost benefits.
Source of Investment FundsNovelStem’s $1 million investment was funded principally by internally generated funds, totaling $750,000. The balance of $250,000 was funded by the sale of 2.5 million shares of NovelStem restricted common stock, priced at $0.10 per share, to an existing NovelStem shareholder.
NewStem CEO Aylet Dilion Mashiah commented, “NewStem is making solid progress advancing its diagnostic technology for anti-cancer drugs resistance. We are privileged working with Novelstem directors to advance this important unmet diagnostic need.”
Jan Loeb, NovelStem Chairman, commented, “We are excited to increase our ownership interest to 27.3% through additional investment comprised primarily of internally-generated funds. We look forward to working closely with the NewStem team and continuing our support of their ground-breaking work.”
About NovelStem International Corp. www.novelstem.com NovelStem has a 27.3% stake in NewStem Ltd. which is advancing novel stem-cell-based diagnostic technology for predicting patients’ resistance to cancer therapies and allowing for better, targeted cancer treatments with the potential to reduce incidents of drug resistance. NovelStem has the right to increase its ownership to 33% based upon completion of an additional investment of $1 million. NovelStem also owns 50% in Netco Partners, which owns the Net Force publishing franchise. NovelStem has 39 million common shares outstanding and substantial net operating loss carryforwards.
About NewStem Ltd.NewStem Ltd. which is advancing novel stem-cell-based diagnostic technology for predicting patients’ resistance to cancer therapy, allowing for better, targeted personal-oncology treatments with the potential to reduce incidents of anti-cancer drug resistance. NewStem is a spinoff of Yissum, The Hebrew University of Jerusalem’s technology-transfer company. NewStem’s diagnostic solutions are based on the research of human haploid pluripotent stem cells (hHPSCs) by Professor Nissim Benvenisty, Director of the Azrieli Center for Stem Cells and Genetic Research at the Hebrew University. NewStem holds the intellectual property, reagents and experience required for hHPSC isolation, differentiation, genetic manipulation, immunogenicity and tumorigenicity.
Forward-Looking Statements Statements in this press release and its hyperlinks may be “forward-looking statements” within the meaning of federal securities laws. The matters discussed herein that are forward-looking statements are based on current board and management expectations that involve risks and uncertainties that may result in such expectations not being realized. Actual outcomes and results may differ materially from what is expressed or forecasted in such forward-looking statements due to numerous potential risks and uncertainties, including, but not limited to, the success of NewStem’s research and future commercialization of its diagnostics utilizing human haploid pluripotent stem cells, competition in the area of genetic diagnostics, the ability to retain key personnel involved in research and development, the ability to secure appropriate regulatory approvals, and the ability to fund future investment in NewStem. Such forward-looking statements speak only as of the date on which they are made.
NovelStem Investor RelationsBill Jones or David Collins Catalyst IR(212) 924-9800NSTM@catalyst-ir.com
georgie18
8年前
HOLL...16...News...Hollywood Media Completes Transformational Investment in NewStem, Israel-Based Developer of Haploid Stem Cell-Based Diagnostics to Predict Chemotherapy Resistance...
Authorized Shares
100,000,000
01/16/2018
Outstanding Shares
16,131,477
01/16/2018
https://backend.otcmarkets.com/otcapi/company/financial-report/202231/content
Details of NewStem Transaction
HMC has completed a $2 million investment in NewStem Ltd., securing an initial 20% ownership in
the company, including its technology, intellectual property and future commercial potential, at a
$10.0 million post-money valuation. HMC has also secured the right to increase its NewStem
ownership up to 33%, based on the completion of up to $2 million in follow-on contributions.
Pending the achievement of certain development milestones, HMC will contribute an additional $1
million in NewStem on each of the 12-month and 18-month anniversaries of its initial contribution.
Currently, the balance of NewStem ownership is evenly divided between Professor Nissim
Benvenisty and Yissum.
Mitchell Rubenstein – Director - Mr. Rubenstein co-founded and served as Chairman of HMC
from its inception to June 2018, during which period the company returned approximately $37
million to shareholders in the form of dividends and share repurchases, including a tender offer.
He founded Syfy Channel and numerous other media businesses.
funnyG986
8年前
HOLL $0.17 DD. It seems another $0.06+ divy on the way and company just sold controlling interest to Leap Tide Capital Management LLC; Plus recent $4M seed funding announcement.
Details of Investment in NovelStem/HMC
The NewStem investment was funded with available cash and proceeds from a $1.925 million investment in HMC at $0.10 per share by an investor group led by Leap Tide Capital Management LLC. The new investors purchased 19.25 million shares, or approximately 54.4% of HMC’s 35.4 million shares outstanding after the investment. Terms of the new investment were based on HMC’s estimated per share value of its current cash position, plus the present value of $600,000 in expected holdback payments from the previous sale of an online ticketing business, which represented approximately $0.10 per share as of June 30, 2018. HMC’s share of the total potential holdback is $1.5 million and any funds received by HMC in excess of $600,000 would be paid to HMC shareholders, excluding those who participated in the recent private placement. There were 16,131,477 HMC shares outstanding prior to the private placement.
Investors in the HMC financing have agreed to an 18-month resale prohibition on their shares, in addition to waving participation in any profits generated by the Netco Partners publishing joint venture over the next 18 months.
https://www.novelstem.com/company-investment-details/
georgie18
8年前
HOLL...21...NewStem Announces $4 million Seed InvestmentPress Release | 07/16/2018...
Authorized Shares
100,000,000
01/16/2018
Outstanding Shares
16,131,477
01/16/2018
https://www.otcmarkets.com/stock/HOLL/news/NewStem-Announces-4-million-Seed-Investment?id=198004
Hollywood Media Completes Transformational Investment in NewStem, Israel-Based Developer of Haploid Stem Cell-Based Diagnostics to Predict Chemotherapy ResistancePress Release | 07/16/2018
Raises $1.925 Million to Support a $2 Million Initial Investment in NewStem Ltd.
Appoints New Board of Directors Led by Jan Loeb as Chairman
Forms New Leadership Team with Deep Healthcare Expertise
Plans to Rename Company NovelStem International Corp.
https://www.otcmarkets.com/stock/HOLL/news/Hollywood-Media-Completes-Transformational-Investment-in-NewStem-Israel-Based-Developer-of-Haploid-Stem-Cell-Based-Diagn?id=198002
Though HMC intends to provide periodic updates via press release as developments warrant, the company intends to remain “dark” for the foreseeable future, also to minimize overhead expense.
Mitchell Rubenstein – Director - Mr. Rubenstein co-founded and served as Chairman of HMC from its inception to June 2018, during which period the company returned approximately $37 million to shareholders in the form of dividends and share repurchases, including a tender offer. He founded Syfy Channel and numerous other media businesses.
Eric Richman – Director - Mr. Richman is a life science executive with significant leadership, operational and strategic experience from over 25 years in the field. He is currently a Venture Partner at Brace Pharma Capital and serves on the boards of LabConnect, F2G (board observer) and ADMA Biologics (NASDAQ: ADMA).
DFRANK1970
8年前
Hollywood Media Advances Pay Date to March 29 for $0.45 per Share Special Distribution
Source: https://www.hollywoodmedia.com/press-release-mar-15-2018
BOCA RATON, FL, March 15, 2018 - Hollywood Media Corp. (OTC Pink: HOLL) today provided updated timing for the record date, pay date and ex-dividend date for its previously announced special $0.45 per share cash distribution to shareholders. The distribution is expected to be classified as a return of capital for tax purposes. The updated distribution details, which were revised in light of the market holiday on March 30, 2018, are as follows:
Special Distribution: $0.45 per common share
Record Date: Friday, March 23, 2018
Pay Date: Thursday, March 29, 2018
Ex-Dividend Date: Monday, April 2, 2018
Shares outstanding: 16,131,477
Total Special Distribution: $7.26 million
About Hollywood Media (www.hollywoodmedia.com)
Hollywood Media Corp. owns a 50% interest in Netco Partners, a joint venture that owns the Net Force publishing franchise, which delves into the thrilling and fast-paced worlds of digital crimes, espionage and crypto-currencies. Hollywood Media plans to relaunch Net Force with new books starting in early 2019.
A story-arc outline for an additional five Net Force books has been completed and the manuscripts for the first two books in the franchise reboot have already been written. A literary agent has been retained to seek publishers to publish these books in four formats – hardcover, eBooks, streaming audio books and podcast editions -- at an anticipated rate of one book launch every 9-12 months.
The initial series of ten Net Force books was published in paperback between 1999 and 2006. Each was a New York Times Bestseller, millions of copies were sold worldwide, and Net Force was also the subject of a TV miniseries on ABC. Cash distributions to Hollywood Media of licensing fees from the Net Force franchise have totaled approximately $11.3 million.
The new Net Force is vastly expanded from its original status as a branch of the FBI. The series is now set in the near future where Net Force is a Cabinet-level department, integrating elite members of the Nation’s intelligence, law enforcement and scientific agencies with dedicated SpecialOps units from the armed services, to investigate digital crimes involving espionage and crypto-currencies.
Forward-Looking Statements
Statements in this press release and its hyperlinks may be “forward-looking statements” within the meaning of federal securities laws. The matters discussed herein that are forward-looking statements are based on current management expectations that involve risks and uncertainties that may result in such expectations not being realized. Actual outcomes and results may differ materially from what is expressed or forecasted in such forward-looking statements due to numerous potential risks and uncertainties, including, but not limited to, the results of the relaunch of the Net Force series and realizing anticipated revenues, the amount of sales of Net Force books, and cost efficiencies, the impact of potential future dispositions or other strategic transactions by Company, our ability to develop and maintain strategic relationships, our ability to compete with other media companies, technology risks, the volatility of our stock price, and other risks and factors. Such forward-looking statements speak only as of the date on which they are made
Investor Relations Contact: David Collins or Chris Eddy Catalyst IR
(212) 924-9800 or holl@catalyst-ir.com
DFRANK1970
8年前
HOLLYWOOD MEDIA (HOLL) Shorts Up By 62.5%
April 18, 2018 - By Winifred Garcia
HOLLYWOOD MEDIA CORP (OTCMKTS:HOLL) had an increase of 62.5% in short interest. HOLL’s SI was 1,300 shares in April as released by FINRA. Its up 62.5% from 800 shares previously. It closed at $0.225 lastly. It is down 0.00% since April 18, 2017 and is . It has underperformed by 11.55% the S&P500.
Analysts expect MGM Growth Properties LLC (NYSE:MGP) to report $0.52 EPS on April, 26 before the open.They anticipate $0.03 EPS change or 6.12% from last quarter’s $0.49 EPS. MGP’s profit would be $138.34M giving it 13.53 P/E if the $0.52 EPS is correct. After having $0.52 EPS previously, MGM Growth Properties LLC’s analysts see 0.00% EPS growth. The stock increased 1.77% or $0.49 during the last trading session, reaching $28.15. About 1.27 million shares traded or 50.45% up from the average. MGM Growth Properties LLC (NYSE:MGP) has risen 0.27% since April 18, 2017 and is uptrending. It has underperformed by 11.28% the S&P500.
Hollywood Media Corp. provides advertising services. The company has market cap of $5.09 million. It operates through Ad Sales and Intellectual Property divisions. It has a 0.82 P/E ratio. The Ad Sales division operates MovieTickets.com that allows users to purchase movie tickets and retrieve them at will call windows or kiosks at theaters.
MGM Growth Properties LLC engages in owning, acquiring, and leasing casino resort properties in the United States. The company has market cap of $7.49 billion. It resorts provide casino gaming, hotel, convention, dining, entertainment, retail, and other resort amenities. It has a 42.01 P/E ratio. As of December 31, 2016, the company??s properties include approximately 27,233 hotel rooms, 2.6 million square feet of convention space, 100 retail outlets, 200 food and beverage outlets, and 20 entertainment venues.
Among 6 analysts covering MGM Growth Properties (NYSE:MGP), 5 have Buy rating, 0 Sell and 1 Hold. Therefore 83% are positive. MGM Growth Properties had 6 analyst reports since May 16, 2016 according to SRatingsIntel. The stock of MGM Growth Properties LLC (NYSE:MGP) has “Buy” rating given on Tuesday, November 22 by Buckingham Research. As per Monday, May 16, the company rating was initiated by Citigroup. The stock of MGM Growth Properties LLC (NYSE:MGP) earned “Buy” rating by Suntrust Robinson on Monday, May 16. Morgan Stanley initiated the stock with “Overweight” rating in Monday, May 16 report. As per Monday, May 16, the company rating was initiated by JP Morgan. Deutsche Bank initiated MGM Growth Properties LLC (NYSE:MGP) on Monday, May 16 with “Buy” rating.
Source: https://flintdaily.com/mgm-growth-properties-mgp-analysts-see-0-52-eps-hollywood-media-holl-shorts-up-by-62-5/
Hot Features
プレミアム
登録してリアルタイムのアラート、カスタムポートフォリオ、市場の動きを入手してください。
ore searcher
3年前
Golden Cross
7年前
Renee
8年前
la_trader
8年前
メールアドレスで登録
